open access
Bivalirudin use in acute coronary syndrome patients undergoing percutaneous coronary interventions in Poland: Clinical update from expert group of the Association on Cardiovascular Interventions of the Polish Cardiac Society
Affiliations- 1st Department of Cardiology, Medical University of Warsaw, Poland
- Department of Interventional Cardiology, Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland
- 2nd Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland
- Department of Epidemiology and Statistics. Medical School of Silesia, Katowice, Poland
- Department of Cardiovascular Research, American Heart of Poland, Ustron, Poland
- Center for Cardiovascular Research and Development, American Heart of Poland, Katowice, Poland
- Andrzej Frycz Modrzewski Krakow University, Krakow, Poland
- 1st Department of Cardiology, Medical University of Gdansk, Poland
- Department of Interventional Cardiology and Angiology, Institute of Cardiology, Warsaw, Poland
- Department of Invasive Cardiology, Medical University of Bialystok, Poland
- Department of Invasive Cardiology of the Center of Postgraduate Medical Education, Central Hospital of the Internal Affairs Ministry and Administration, Warsaw, Poland
- Department of Cardiology, Pomeranian Medical University, Szczecin, Poland
- Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
- Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
- Department and Clinic of Cardiology, Wroclaw Medical University, Wroclaw, Poland
- Invasive Cardiology and Electrocardiology Department, Medical University of Silesia, Katowice Poland
- Department of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland
- Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
- “IKARDIA” Hospital of Invasive Cardiology, Naleczow, Poland
- 2nd Department of Clinical Cardiology and Cardiovascular Interventions, Jagiellonian University Hospital, Krakow, Poland
- Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland
open access
Abstract
Abstract
About this articleTitle
Bivalirudin use in acute coronary syndrome patients undergoing percutaneous coronary interventions in Poland: Clinical update from expert group of the Association on Cardiovascular Interventions of the Polish Cardiac Society
Journal
Issue
Pages
1-7
Published online
2019-03-14
Page views
2919
Article views/downloads
1586
DOI
10.5603/CJ.2019.0029
Pubmed
Bibliographic record
Cardiol J 2019;26(1):1-7.
Authors
Łukasz Kołtowski
Jacek Legutko
Krzysztof J. Filipiak
Artur Dziewierz
Stanisław Bartuś
Paweł Buszman
Piotr Buszman
Dariusz Ciećwierz
Maciej Dąbrowski
Sławomir Dobrzycki
Robert Gil
Jarosław Gorący
Marek Grygier
Miłosz Jaguszewski
Janusz Kochman
Jacek Kubica
Wiktor Kuliczkowki
Piotr Lodziński
Andrzej Ochała
Krzysztof Reczuch
Adam Witkowski
Wojciech Wojakowski
Jarosław Wójcik
Dariusz Dudek
References (26)- Sanchis-Gomar F, Perez-Quilis C, Leischik R, et al. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016; 4(13): 256.
- Wożakowska-Kapłon B, Lesiak M, Ochała A, et al. [Bivalirudine use in the acute myocardial infarction in patients undergoing percutaneous coronary interventions: consensus statement of experts from the Cardiovascular Pharmacotherapy Working Group and the Association on Cardiovascular Interventions of the Polish Cardiac Society]. Kardiol Pol. 2014; 72(8): 761–765.
- Valgimigli M, Frigoli E, Leonardi S, et al. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet. 2018; 392(10150): 835–848.
- Shah R, Jovin IS, Chaudhry A, et al. Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention. Catheter Cardiovasc Interv. 2019; 93(2): 241–247.
- Anantha-Narayanan M, Anugula D, Gujjula NR, et al. Bivalirudin versus heparin in percutaneous coronary intervention-a systematic review and meta-analysis of randomized trials stratified by adjunctive glycoprotein IIb/IIIa strategy. J Thorac Dis. 2018; 10(6): 3341–3360.
- Grajek S, Michalak M, Gwizdała A, et al. Patients treated with bivalirudin are still at higher risk of stent thrombosis: a comprehensive meta-analysis of randomised clinical trials of bivalirudin and heparin for percutaneous coronary interventions. Kardiol Pol. 2018; 76(4): 740–749.
- Neumann F-J, Ahlsson A, Alfonso F, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2018; 34(10): 2949.
- Kereiakes D, Yeh R, Massaro J, et al. Stent thrombosis in drug-eluting or bare-metal stents in patients receiving dual antiplatelet therapy. JACC: Cardiovasc Interv. 2015; 8(12): 1552–1562.
- Kam PCA, Kaur N, Thong CL. Direct thrombin inhibitors: pharmacology and clinical relevance. Anaesthesia. 2005; 60(6): 565–574.
- Alquwaizani M, Buckley L, Adams C, et al. Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. Curr Emerg Hosp Med Rep. 2013; 1(2): 83–97.
- Cannon CP, Maraganore JM, Loscalzo J, et al. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol. 1993; 71(10): 778–782.
- Stratmann G, deSilva A, Tseng E, et al. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg. 2004: 1635–1639.
- Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med. 2015; 373(11): 997–1009.
- Erlinge D, Omerovic E, Fröbert O, et al. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. N Engl J Med. 2017; 377(12): 1132–1142.
- Witkowski A, Barylski M, Filipiak KJ, et al. Non-vitamin K antagonist oral anticoagulants (NOACs) in the treatment of coronary and peripheral atherosclerosis. Expert Consensus. Kardiol Pol. 2019 [Epub ahead of print].
- Mallifi JR, Lotfi AS. Management of STEMI in Patients on NOACs and Undergoing Primary PCI. Expert Analysis ACC website 2015. https://www.acc.org/latest-in-cardiology/articles/2015/10/22/10/43/management-of-stemi-in-patients-on-noacs-and-undergoing-primary-pci.
- Wojtasik-Bakalarz J, Kleczyński P, Zasada W, et al. Safety of bivalirudin versus unfractionated heparin in endovascular revascularization of peripheral arteries in short- and long-term follow-up. Advances in Inverventional Cardiology. .
- Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. 2012; 307(17): 1817–1826.
- Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008; 358(21): 2218–2230.
- Stone G, McLaurin B, Cox D, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006; 355(21): 2203–2216.
- Steg PG, van 't Hof A, Hamm CW, et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med. 2013; 369(23): 2207–2217.
- Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11): 1045–1057.
- Wiviott S, Braunwald E, McCabe C, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2007; 357(20): 2001–2015.
- Koster A, Faraoni D, Levy JH. Argatroban and bivalirudin for perioperative anticoagulation in cardiac surgery. Anesthesiology. 2018; 128(2): 390–400.
- Schwenkglenks M, Brazier JE, Szucs TD, et al. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes. Value Health. 2011; 14(1): 24–33.
- Borg S, Persson U, Allikmets K, et al. Comparative cost-effectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-receptor inhibitor in patients undergoing percutaneous coronary intervention in Sweden: a decision-analytic model. Clin Ther. 2006; 28(11): 1947–1959.
